Everything drug pricing and policy, every day
Plus new research on the financial impact of Alzheimer’s disease
And Trump’s overseas visit puts a new lens on the industry-vs-government showdown in the UK
I’m out of position today, but you should be tracking on 340B news and odds that PBM reform happens this year
And a gathering of congressional staffers and health policy pros in Washington on MFN offers little perspective on next steps
And looking at how Eisai talked value around the launch of its subcutaneous Alzheimer’s drug
And the Washington Post, NPR, Axios, and CNBC all jumped on the biggest story in health policy right now
And how a small biotech is leading the way in talking about contracting for its medicine
It’s a drinking-from-a-firehose kind of morning
And is PBM reform about to mount a comeback? (I mean, the answer is pretty much “no,” but the topic is circulating again)
